Castle Biosciences: Revenue Up, Stock Climbs
Castle Biosciences Stock Climbs on Strong Revenue Growth, Lifted Outlook Despite Net Loss
Anonymous
Key Points
1
In Q2 2026 Castle Biosciences posted a net loss of about $2.1 million and a basic loss per share of $0.07, reversing Q2 2025's $4.5 million profit and $0.16 per-share gain.
2
TissueCypher volumes rose 63% to 14,988 reports, and DecisionDx-Melanoma volumes ticked higher, with a new prospective multicenter study aligning with NCCN risk thresholds; AdvanceAD-Tx cleared a payer milestone via a unanimous crosswalk panel vote and a proposed US$3,675 CLFS rate.
3
Insider activity showed the CEO sold 9,836 Castle Biosciences shares on July 1 under a pre-arranged plan.
4
Management raised the 2026 revenue outlook to $365–375 million, with gross profit up about 16.5% to $79.8 million and operating cash flow of $15.2 million, while the company held about $62.1 million in cash at quarter-end.
5
Analyst sentiment remains constructive but varied, including Wall Street Zen upgrading CSTL to Hold and MarketBeat’s consensus rating at Moderate Buy with an average target around $41.43.
Castle Biosciences stock jumped about 4.5% to roughly $28 after the company posted strong second-quarter results and lifted its full-year revenue target. Simply Wall St reported that Q2 revenue hit $103.5 million, a 20% rise from the same period last year, pushing management to raise its 2026 revenue guidance to $365–$375 million, up from the prior range of $345–$355 million.
The gain came even though Castle posted a net loss of about $2.1 million, or $0.07 per share, reversing a $4.5 million profit in Q2 2025. Investors focused on the top-line growth and the higher outlook rather than the red ink.
TissueCypher Volumes Surge 63% in Key Quarter
The standout driver was TissueCypher, a test that helps detect cancer risk in Barrett's esophagus patients. According to Guru Focus, TissueCypher report volume jumped 63% year over year to 14,988 reports in the quarter. Management now expects TissueCypher volume growth of 50–52% for the full year.
DecisionDx-Melanoma volumes also ticked higher. A new prospective multicenter study aligned the test with NCCN risk thresholds, which could help drive broader adoption. Another product, AdvanceAD-Tx, cleared a key payer hurdle with a unanimous crosswalk panel vote and a proposed reimbursement rate of $3,675.
Margins Improve Even as Losses Narrow Slightly
Gross profit rose about 16.5% to $79.8 million for the quarter. Operating cash flow came in at $15.2 million, a sign the business is generating real cash even while still reporting a net loss. The company held about $62.1 million in cash at quarter-end, giving it runway to keep investing in growth.
Simply Wall St described the stock as a potential mispricing story, noting that top-line momentum and improving cash flow matter more to investors right now than the bottom-line loss. Gross margins are moving in the right direction, even if full profitability is still ahead.
Analysts Lean Bullish With Average Target Near $43
Wall Street sentiment is broadly positive. TradingView reported that the average 12-month price target across nine analysts rose from $42.78 to $43, implying roughly 61% upside from current levels. Roth Capital initiated coverage with a Buy rating and a $40 target, citing strong revenue growth and a clear path to profitability.
MarketBeat's consensus rating sits at Moderate Buy, with an average target of about $41.43. Wall Street Zen upgraded shares to Hold. The range of targets and ratings reflects real debate about when Castle will reach sustained profitability, but the overall tilt remains constructive.
CEO Sold Shares Just Before Earnings Beat
On July 1, Castle Biosciences' CEO sold 9,836 shares under a pre-arranged trading plan. Pre-arranged plans, known as 10b5-1 plans, let executives sell shares on a set schedule regardless of what they know about upcoming results. The sale took place about a month before the strong Q2 report.
Insider sales under pre-arranged plans are legal and common. Still, investors often watch them closely. The sale did not appear to dampen enthusiasm, as the stock rose sharply after Castle reported its results and raised guidance on July 31, according to Seeking Alpha.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
18
Articles
32
Reach
50
A
AnonymousAuthor